Combination of Melatonin and Metformin Hydrochloride for Treatment Polycystic Ovarian in Female Rats

Ana Janaina Jeanine Martins de Lemos-Jordão, Fabiano Sellos Costa, Christina Alvez Peixoto, Álvaro Aguiar Coelho Teixeira, Solange Bezerra da Silva, Cintia Giselle Martins Ferreira, Anne Gabrielle Vasconcelos de Oliveira, Rayana Leal Luna, Eduardo Pereira Duarte Silva, Carolline Guimarães D’assunção, Valéria Wanderley-Teixeira

Abstract


Background: Polycystic ovary syndrome (PCOS) is a gynecological endocrine disorder, results in menstrual abnormalities, androgynism and infertility. In the case of women or others animals with PCOS wishing to treat infertility with the aim of becoming pregnant, the most commonly used is metformin hydrochloride. Recent studies have analyzed the combination of metformin hydrochloride with melatonin in oncological treatment but not to treatment of polycystic ovary syndrome (PCOS). The aim of the present study was to analyze the effectiveness of the combination of metformin hydrochloride and melatonin in the treatment of PCOS to improve the fertility of rats and your hormonal alterations.

Materials, Methods & Results: This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Committee on the Ethics of Animal Experiments of the University of Federal Rural of Pernambuco (Permit Number: 23081.009130/2010). A total of 50 albino Wistar rats were used. The animal laboratory of an academic research environment, were randomly separated into five groups consisting of 10 females each. After inducing PCOS, the rats were treated with metformin hydrochloride, and/or melatonin, and the results compared with standard and ultrasound confirmed. The physiological similarities were confirmed by our academic researchers morphological science, and published to the association results of effects syndrome induction through constant lighting in reputable magazine recently. This article was analyzed histological of the implantation sites and ovaries, and the estradiol and progesterone levels on the seventh day of gestation, and the other rats for monitoring pregnancy and morphological identification of possible fetal abnormalities, weight measurement and quantification of offspring. The rats were anaesthetized with intraperitoneal injections of ketamine hydrochloride (80 mg/kg) and xylazine (6 mg/kg) to allow analysis of the reproductive organs. Main outcome measures: The study included histopathology, histochemical and quantitative (of the implantation sites) tests, ultrasound analysis, weight benchmarking and ovarian histology tests, as well as comparison of serum estradiol and progesterone levels, and the morphological assessment of offspring. Results paper shows pharmacological treatment reduced the time needed for pregnancy, increased the plasma progesterone levels, the number and weight of offspring, and reduced plasma estrogen levels and collagen fiber grade, improving blastocyst-endometrium interaction and fetal development.

Discussion: Our team of researchers confirmed in a previous paper; in addition, the main experimental model used in research about PCOS in recent years, and considered appropriate combination of the drugs caused a physiological reaction similar to responses identified in healthy rats without induction of the POS control group. However, the clinical and physiological effectiveness of the combination should be further explored, especially with respect to the possible side effects on offspring. The treatment with a combination of metformin hydrochloride and melatonin was more effective against hormonal alterations produced by PCOS, allowing a normalization of biochemical parameters during pregnancy, than monotherapeutic treatment with these drugs. In conclusion, proposed drug combination is a viable option to treatment of polycystic ovary syndrome and improved fetal development. This article allows suggest that further research should be conducted to examine effects associated with these drugs in the treatment of diseases of the female reproductive system experimentally. Only such treatment later in animals and humans suggest.


Keywords


polycystic ovaries; metformin; melatonin; reproduction; estradiol; progesterone.

Full Text:

PDF

References


Anisimov V.N. 2003. Effects of exogenous melatonin - A Review. Toxicologic Pathology. 31(1): 589-603.

Anisimov V.N., Egormin P.A., Piskunova T.S., Popovich I.G., Tyndyk M.L. & Yurova M.N. 2010. Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle. 9(1): 188-197.

Attia G.R., Rainey W.E. & Carr B.R. 2001. Metformin directly inhibits androgen production in human thecal cells. Fertility and Sterility. 76(3): 517-524.

Batista C.P.A., Medeiros P.L., Teixeira A.A.C. & Wanderley-Teixeira V. 2009. Análises histoquímica e morfométrica de lesões endometrióticas induzidas em ratas e tratadas com dexametasona. Jornal Brasileiro de Patologia e Medicina Laboratorial. 45(2): 147-153.

Berger J. 2008. A two-clock model of circadian timing in the immune system of mammals. Pathologie Biologie. 56(5): 286-291.

Chuffa L.G.A, Seiva F.R.F., Fávaro W.J., Teixeira G.R., Amorim J.P.A., Mendes L.O., Fioruci B.A., Pinheiro P.F., Fernandes A.A., Franci J.A., Delella F.K., Martinez M. & Martinez F.E. 2009. Melatonin reduces LH, 17beta-estradiol and induces differential regulation of sex steroid receptors in reproductive tissues during rat ovulation. Reproductive Biology and Endocrinology. 9(108): 1-9.

Diamanti-Kandaraki E., Christakou C.D., Kandaraki E. & Economou F.N. 2010. Metformin: An old medication of new fashion: Evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. European Journal of Endocrinology. 162(1): 193-212.

Diamanti-Kandaraki E., Economou F., Palimeri S. & Christakou C. 2010. Metformin in polycystic ovary syndrome. Annals of the New York Academy of Sciences. 1205(1): 192-198.

Drobnik J., Karbownik-Lewinska M., Szczepanowska A., Slotwinska O.S., Jakubowski L. & Dabrowski R. 2008. Regulatory influence of melatonin on collagen accumulation in the infarcted heart scar. Journal of Pineal Research. 45(3): 285-290.

Elia E., Sander V., Luchetti C.G., Solano M.E., Di-Girolamo G. & Gonzalez C. 2006. The mechanisms involved in the action of metforminin regulating ovarian function in hyperandrogenized mice. Molecular Human Reproduction. 12(8): 475-481.

Elias J.A.Z., Delfino V.D.A., Barbosa D.S., Fabris B.A. & Matsuo T. 2008. Efeito do Ramipril e da Sinvastatina sobre o estresse oxidativo de ratos diabéticos. Arquivos Brasileiros de Endocrinologia & Metabologia. 52(7): 1131-1138.

Gambineri A., Patton L., Altieri P., Pagotto U., Pizzi C. & Manzoli L. 2012. Polycystic ovary syndrome is a risk factor for type 2 diabetes: Results from a long-term prospective study. Diabetes. 61(9): 2369-2374.

Ganie M.A., Khurana M.L., Eunice M., Gulati M., Dwivedi S.N. & Ammini A.C. 2004. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. The Journal of Clinical Endocrinology & Metabolism. 89(6): 2756-2818.

Hyderali B.N. & Mala K. 2015. Oxidative stress and cardiovascular complications in polycystic ovarian syndrome. European journal of obstetrics, gynecology, and reproductive biology. 191(1): 15-22

Jakubowicz D., Iuorno M.J., Jakubowicz S., Roberts K.A. & Nestler J.E. 2002. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism. 57(8): 524529.

Lemos A.J.J.M., Peixoto C.A., Teixeira A.A.C., Luna R.L.A., Rocha S.W.S., Santos H.M.P., Silva A.K.S., Nunes A.K.S. & Wanderley-Teixeira V. 2014. Effect of the combination of metformin hydrochloride and melatonin on oxidative stress before and during pregnancy, and biochemical and histopathological analysis of the livers of rats after treatment for polycystic ovary syndrome. Toxicology and Applied Pharmacology. 280(1): 159-168.

Man’cheva T.A., Demidov D.V., Plotnikova N.A., Kharitonova T.V., Pashkevich I.V. & Anisimov V.N. 2011. Melatonin and metformin inhibit skin carcinogenesis, and lipid peroxidation induced by benz(a)pyrenein female mice. Bulletin of Experimental Biology and Medicine. 151(30029): 339-342.

Mansfield R., Galea R., Brincat M., Hole D. & Mason H. 2003. Metformin has direct effects on human ovarian steroidogenesis. Fertility and Sterility. 79(4): 956-962.

Mason H.D., Willis D.S., Beard R.W., Winston R.M., Margara R. & Franks S. 1994. Estradiol production by granulosa cells of normal and polycystic ovaries: Relationship to menstrual cycle history and concentrations of gonadotropins and sex steroids in follicular fluid. The Journal of Clinical Endocrinology & Metabolism. 79(5): 1355-1360.

Meenakumari K.J., Agarwal S., Krishna A. & Pandey L.K. 2004. Effects of metformin treatment on luteal phase progesterone concentration in polycystic ovary syndrome. Brazilian Journal of Medical and Biological Research. 37(11): 1637-1644.

Metallinou C., Asimakopoulos B., Schröer A. & Nikolettos N. 2007. Gonadotropin-releasing hormone in the ovary. Reproductive Sciences. 14(8): 737-749.

Modugno F., Weissfeld J.L., Trump D.L., Zmuda J.M., Shea P. & Cauley J.A. 2001. Allelic Variants of Aromatase and the Androgen and Estrogen Receptors: Toward a Multigenic Model of Prostate Cancer Risk Toward a multigenic model of prostate cancer risk. Clinical Cancer Research. 7(1): 3092-3096.

Nestler J.E., Jakubowicz D.J., Evans W.S. & Pasquali R. 1998. Effects of metformin on spontaneous and clomipheneinduced ovulation in the polycystic ovary syndrome. The New England Journal of Medicine. 338(26): 1876-1880.

Peres M.F.P., Masruha M.R. & Rapoport A.M. 2007. Melatonin therapy for headache disorders. Drug Development Research. 68(6): 329-334.

Prata-Lima M.F., Baracat E.C. & Simões M.J. 2004. Effects of melatonin on the ovarian response to pinealectomy or continues light in female rats: Similarity with polycystic ovary syndrome. Brazilian Journal of Medical and Biological Research. 37(7): 987-995.

Rahima A. & Soderwall A.L. 1977. Uterine collagen content in young and senescent pregnant golden hamsters. Journal of Reproduction & Infertility. 49(1): 161-162.

Salvetti N.R., Canal A.M., Gimeno E.J. & Ortega H.H. 2004. Polycystic Ovarian Syndrome: Temporal characterization of the induction and reversion process in an experimental model. Brazilian Journal of Veterinary Research and Animal Science. 41(6): 389-395.

Sander V., Luchetti C.G., Solano M.E., Elia E., Di Girolamo G., Gonzalez C. & Motta A.B. 2006. Role of the N, N’-dimethylbiguanide metformin in the treatment of female prepuberal BALB/c mice hyperandrogenized with dehydroepiandrosterone. Reproduction. 131(1): 591-602.

Sekhon L.H., Gupta S., Kim Y. & Agarwal A. 2010. Female infertility and antioxidants. Current Women’s Health Reviews. 6(2): 84-95.

Shi D. & Vine D.F. 2012. Animal models of polycystic ovary syndrome: a focused review of rodent models in relationship to clinical phenotypes and cardiometabolic risk. Fertility and Sterility. 98(1): 185-193.

Singh K.B. 2005. Persistent estrus rat models of polycystic ovary disease: An update. Fertility and Sterility. 84(Suppl 2): 1228-1234.

Taketani T., Tamura H., Takasaki A., Lee L., Kizuka F., Tamura I., Taniguchi K., Maekawa R., Asada H., Shimamura K., Reiter R.J. & Sugino N. 2011. Protective role of melatonin in progesterone production by human luteal cells. Journal of Pineal Research. 51(2): 207-213.

Tamura H., Nakamura H., Korkmaz A., Manchester L.C., Tan D.X., Sugino N. & Reiter R.J. 2009. Melatonin and the ovary: physiological and pathophysiological implications. Fertility and Sterility. 92(1): 328-343.

Teixeira A.A.C., Simões M.J., Evêncio-Neto J. & Wanderley-Teixeira V. 2002. Morphologic aspects of the endometrium, in the estrus phase, of pinealectomized rats. Revista Chilena de Anatomía. 20(2): 145-149.

Teixeira A.A.C., Simões M.J., Wanderley-Teixeira V. & Soares-Junior J.M. 2004. Evaluation of the implantation in pinealectomized and/or submitted to the constant illumination rats. International Journal of Morphology. 22(3): 189-194.

Vilaça-Junior P.E.A., Soares A.F., Wanderley-Teixeira V., Araújo A.C.C. & Teixeira A.A.C. 2012. Efeito da administração pré-natal da dexametasona em ratas sobre os perfis glicídicos e hematológicos materno e da prole. Arquivo Brasileiro de Medicina Veterinária e Zootecnia. 64(3): 606-614.

Vilar L., Canadas V., Arruda M.J., Arahata C., Agra R. & Pontes L. 2010. Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes. Arquivos Brasileiros de Endocrinologia & Metabologia. 54(6): 311-318.

Walters K.A., Allan C.M. & Handelsman D.J. 2012. Rodent Models for Human Polycystic Ovary Syndrome. Biology of Reproduction. 86(5): 1-12.

Woo M.M.M., Tai C., Kang S.K., Nathwani S., Pang S.F. & Leung C.K. 2010. Direct action of melatonin in human granulosa-luteal cells. The Journal of Clinical Endocrinology & Metabolism. 86(10): 4789-4797.

Xie Y., Wang Y., Yu L., Hu Q., Li L., Zang Y. & Liao Q.P. 2011. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. The Journal of Steroid Biochemistry and Molecular Biology.126(3-5): 113-120.

Zhang X., Zhang C., Shen S., Xia Y.j., Yi L., Gao Q. & Wang Y. 2013. Dehydroepiandrosterone induces ovarian and uterine hyperfibrosis in female rats. Human Reproduction. 28(11): 3074-3085.




DOI: https://doi.org/10.22456/1679-9216.81208

Copyright (c) 2018 Ana Janaina Jeanine Martins de Lemos-Jordão, Fabiano Sellos Costa, Christina Alvez Peixoto, Álvaro Aguiar Coelho Teixeira, Solange Bezerra da Silva, Cintia Giselle Martins Ferreira, Anne Gabrielle Vasconcelos de Oliveira, Rayana Leal Luna, Eduardo Pereira Duarte Silva, Carolline Guimarães D’assunção, Valéria Wanderley-Teixeira

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.